CLL Society News Archives

August 26, 2022

Dr. Brian Koffman Shares His Experience Receiving Evusheld with ASPR to Increase Awareness and Access Across Healthcare Practices in the United States

CLL Society believes that every immunocompromised individual, including those with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), regardless of treatment status, should experience easy access to the life-saving pre-exposure prophylaxis therapy or PreP, Evusheld.

August 25, 2022

We Need Your Help: The FDA Will Be Reviewing Whether Duvelisib Should Be Withdrawn or Continue to be Approved for Relapsed/Refractory CLL

CLL Society would like to make a special request to all of those who have CLL/SLL in our community to please consider submitting a personal comment to the FDA regarding the possibility of duvelisib being removed as an available treatment option.

August 19, 2022

Announcing the Winner of CLL Society’s First Ever Young Investigator Research Program Award: Dr. Christine Ryan on the Topic of Richter’s Syndrome

In January 2022, CLL Society formally announced the launch of a new Research Program that is devoted to supporting underfunded areas of bench and translational science to make progress in the following four critical areas of unmet needs for those diagnosed with CLL/SLL:

August 15, 2022

The National Institutes of Health (NIH) Now Recognize those with CLL/SLL as Being Immunocompromised, Regardless of Treatment Status

July 1, 2022

CLL Society Requests the FDA to Allow for Continued Use of Already Approved PI3K Inhibitors in CLL/SLL Patients with No Other Approved Treatment Options

In June 2022, CLL Society penned a letter to the FDA that received signatures of support from 40 of the top CLL/SLL physicians in the country.

June 24, 2022

International Advocacy Group Kicks Off Global Campaign Aimed at Highlighting the Needs of Immunocompromised Blood Cancer Patients

CLL Society is proud to have led the establishment of an international group of individuals who all had the same goal in mind―coming together to help protect immunocompromised (IC) blood cancer patients against COVID-19.

June 2, 2022

Dr. Brian Koffman Was Invited to Speak at the Congressional Personalized Medicine Caucus Briefing on Cell and Gene Therapy

This April, CLL Society’s Co-Founder, Executive Vice President, and Chief Medical Officer was invited by the Personalized Medicine Coalition to speak virtually before the Congressional Briefing on Cell and Gene Therapy. He was joined by other impressive experts, members of Congress, and patient advocates.

April 22, 2022

Patty Koffman Retirement Announcement

After nine years of dedicated service to CLL Society, Patty Koffman, co-founder and communications director for CLL Society, will officially retire from her full-time position with CLL Society on April 30. Patty announced this decision to the Board of Directors in May 2021, allowing us ample time to prepare

March 10, 2022

Dr. Koffman Quoted in LA Times: This Treatment Can Protect Vulnerable People From COVID-19. But Many Don’t Know About It

Our own Dr. Koffman is quoted in his local paper, the LA Times, in this article: This Treatment Can Protect Vulnerable People From COVID. But Many Don’t Know About It.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

CLL Society News

Dr. Brian Koffman Shares His Experience Receiving Evusheld with ASPR to Increase Awareness and Access Across Healthcare Practices in the United States

We Need Your Help: The FDA Will Be Reviewing Whether Duvelisib Should Be Withdrawn or Continue to be Approved for Relapsed/Refractory CLL

Announcing the Winner of CLL Society’s First Ever Young Investigator Research Program Award: Dr. Christine Ryan on the Topic of Richter’s Syndrome

The National Institutes of Health (NIH) Now Recognize those with CLL/SLL as Being Immunocompromised, Regardless of Treatment Status

CLL Society Requests the FDA to Allow for Continued Use of Already Approved PI3K Inhibitors in CLL/SLL Patients with No Other Approved Treatment Options

International Advocacy Group Kicks Off Global Campaign Aimed at Highlighting the Needs of Immunocompromised Blood Cancer Patients

Dr. Brian Koffman Was Invited to Speak at the Congressional Personalized Medicine Caucus Briefing on Cell and Gene Therapy

Patty Koffman Retirement Announcement

Dr. Koffman Quoted in LA Times: This Treatment Can Protect Vulnerable People From COVID-19. But Many Don’t Know About It

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT